Diarylethylamine

Research

A number of 1,2-diarylethylamines have been explored in pharmaceutical research. Clinical analogs such as lanicemine (AZD6765) and remacemide have shown potential in the treatment of depression, epilepsy, and neurodegenerative diseases. Diphenidine and ephenidine have been used in animal models to investigate NMDAR-mediated neurophysiological processes, including synaptic plasticity and long-term potentiation. The unique pharmacological profiles of these compounds have also made them subjects of interest in studies of schizophrenia and psychosis. Despite promising in vitro and in vivo data, no 1,2-diarylethylamines have yet achieved widespread medical approval for psychiatric or analgesic indications.